Department for Oncology, Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis, Serbia.
Faculty of Medicine, University of Nis; BioStat.
Pharmazie. 2024 Oct 1;79(9):195-201. doi: 10.1691/ph.2024.4570.
The incorporation of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has redefined therapeutic strategies for advanced ovarian cancer. This study evaluates the efficacy of bevacizumab combined with standard chemotherapy by comparing progression-free survival (PFS) and overall survival (OS) outcomes with a historical cohort of patients treated with standard chemotherapy alone. We conducted an analysis of 71 patients with advanced epithelial ovarian cancer treated at the University Clinical Center in Niš, Serbia, from April 2017 to March 2023. All patients received standard chemotherapy paired with bevacizumab and were monitored for progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier estimates. Subgroup analyses were performed based on age, ECOG performance status, presence of metastases, and pleural effusion. Additionally, a historical cohort of 30 patients treated with standard chemotherapy alone was used for comparison, and Cox regression analysis was conducted to identify factors influencing treatment outcomes. The study findings indicate significant improvements in median PFS (20 months vs. 15 months) and OS (58 months vs. an undetermined upper limit) compared to the historical cohort. Subgroup analysis of the bevacizumab-treated group revealed that younger patients (<65 years) and those without metastases or pleural effusion exhibited notably better survival outcomes. The hazard ratio for PFS in patients younger than 65 was 0.65 (95% CI: 0.45-0.93), suggesting a substantial reduction in disease progression risk compared to older patients. Bevacizumab, when used alongside standard chemotherapy, significantly extends both PFS and OS in patients with advanced ovarian cancer. These benefits are particularly pronounced in younger patients. The results underscore the necessity of integrating bevacizumab into the treatment regimen for advanced ovarian cancer, advocating for tailored therapeutic strategies based on individual risk profiles and clinical characteristics. This study reinforces the pivotal role of bevacizumab in enhancing the current ovarian cancer treatment landscape and highlights the potential for further personalizing oncological care.
贝伐珠单抗是一种针对血管内皮生长因子（VEGF）的单克隆抗体，它的加入重新定义了晚期卵巢癌的治疗策略。本研究通过比较无进展生存期（PFS）和总生存期（OS），评估了贝伐珠单抗联合标准化疗的疗效，与单独接受标准化疗的历史队列患者进行比较。
我们分析了 2017 年 4 月至 2023 年 3 月在塞尔维亚尼什大学临床中心治疗的 71 例晚期上皮性卵巢癌患者。所有患者均接受标准化疗联合贝伐珠单抗治疗，并采用 Kaplan-Meier 估计法监测无进展生存期（PFS）和总生存期（OS）。根据年龄、ECOG 表现状态、是否存在转移和胸腔积液进行亚组分析。此外，还使用了 30 例单独接受标准化疗的历史队列进行比较，并进行 Cox 回归分析以确定影响治疗结果的因素。
研究结果表明，与历史队列相比，中位 PFS（20 个月 vs. 15 个月）和 OS（58 个月 vs. 未确定的上限）均有显著改善。贝伐珠单抗治疗组的亚组分析显示，年轻患者（<65 岁）和无转移或胸腔积液的患者生存结局明显更好。65 岁以下患者的 PFS 风险比为 0.65（95%CI：0.45-0.93），表明与老年患者相比，疾病进展风险显著降低。
贝伐珠单抗联合标准化疗可显著延长晚期卵巢癌患者的 PFS 和 OS。这些益处在年轻患者中更为显著。结果强调了将贝伐珠单抗纳入晚期卵巢癌治疗方案的必要性，提倡根据个体风险概况和临床特征制定个体化治疗策略。本研究强调了贝伐珠单抗在增强当前卵巢癌治疗格局中的关键作用，并突显了进一步实现肿瘤个体化治疗的潜力。
